Somebody promised you a fifth of your body weight, then a pharmacy filled a box with the diabetes version of the drug. That gap is where the money and the disappointment live. Mounjaro for weight loss is a use the FDA has not approved, and the weight result printed on the Mounjaro label is a mean 11.2 kg at the 15 mg dose after 40 weeks, measured in people with type 2 diabetes whose starting weight averaged 93.8 kg (Mounjaro prescribing information, DailyMed, version 40, published 2 September 2026).
The short answer, for anyone who wants it before the argument: Mounjaro is approved for type 2 diabetes and for cardiovascular risk in adults with type 2 diabetes, so the 20.9 percent figure quoted at you comes from a different approval, Zepbound, which carries the same molecule under a separate label.
We will take a side here and stay on it. The two brands are the same chemical, tirzepatide. The difference is paperwork, and the paperwork decides what a prescriber can put on your script, which trial number gets quoted at you, and what your insurer was told the drug is for.
The Mounjaro Label – The Word Obesity Does Not Appear
Read the current Mounjaro prescribing information from the first page to the last and count the appearances of obesity or obese. The count is zero, checked against the full text on 25 October 2026.
Section 1 of that label lists two indications: improve glycemic control in adults and in pediatric patients 10 years and older with type 2 diabetes, and reduce the risk of cardiovascular death, heart attack or stroke in adults with type 2 diabetes at high cardiovascular risk. Nothing in those sentences involves a scale.
A 43-year-old with a BMI of 31 and normal blood sugar fits neither clause. That person can still be prescribed the drug. The label does not describe them, no trial enrolled them under that brand, and no mean result answers their question.
SURPASS-2 – The Mounjaro for Weight Loss Number Is 11.2 kg
The clinical studies section carries the tables, and they are unglamorous in the best way. SURPASS-2 randomized 1,879 adults with type 2 diabetes on metformin, mean BMI 34, to Mounjaro 5, 10 or 15 mg or to semaglutide 1 mg for 40 weeks. Body weight fell 5.7 kg on semaglutide, 7.6 kg on Mounjaro 5 mg, 9.3 kg on 10 mg and 11.2 kg on 15 mg. The differences against semaglutide were 1.9, 3.6 and 5.5 kg, with p<0.001 in the published trial (Frías et al., NEJM 2021;385:503-515, 5 August 2021).
Read the shape of 11.2 kg carefully. It is a mean, at week 40, in a trial designed to measure blood sugar, among people whose average starting weight was 93.8 kg, which puts the average finisher near 82.6 kg. The semaglutide arm started at 93.7 kg, so this was two groups of similarly sized patients, not a stacked comparison.
SURPASS-1, the placebo-controlled monotherapy trial of 478 patients, tells the story again from a smaller starting point: 1.0 kg lost on placebo, 6.3 kg on 5 mg, 7.0 kg on 10 mg and 7.8 kg on 15 mg at week 40. The placebo column is the part the advertising leaves out.
SURMOUNT-2 – Same Molecule, Same Diabetes, 14.7 Percent
Open the Zepbound label and the same molecule posts bigger numbers, because the trial was built to chase weight. Study 1, in adults with obesity or overweight and without diabetes, ran 72 weeks: placebo lost 3.1 percent, and the 5, 10 and 15 mg arms lost 15.0, 19.5 and 20.9 percent from a mean starting weight of 105.6 kg. Study 2, in adults with type 2 diabetes, lost 3.2 percent on placebo, 12.8 percent at 10 mg and 14.7 percent at 15 mg from 99.6 kg (Zepbound prescribing information, DailyMed, Table 2).
Run the arithmetic on those percentages and the distance is concrete. A person at the Study 1 average of 105.6 kg who hits the 20.9 percent mean ends near 83.5 kg, which is 22.1 kg down. A person at the Study 2 average of 99.6 kg who hits the 14.7 percent mean ends near 85 kg, which is 14.6 kg down. Diabetes alone costs about 7.5 kg of the headline promise, before anyone mentions biology, adherence or the 40 week versus 72 week difference in the two designs.
The molecule did not change between those tables. The patients did, and so did the endpoint.
John Sharretts – The FDA Said It Out Loud in 2023
The FDA approved Zepbound on 8 November 2023, and its announcement explained the split in plain language. Tirzepatide, it said, is already approved under the trade name Mounjaro to improve blood sugar in adults with type 2 diabetes (FDA, FDA Approves New Medication for Chronic Weight Management, 8 November 2023).
John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, put the stakes in the release: “Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes.”
The same release contains a line worth reading twice. Zepbound should not be used in combination with Mounjaro or a GLP-1 receptor agonist. That is the regulator stating, in a safety sentence, that the two brands are one drug.
Off-Label – A Mounjaro for Weight Loss Prescription Is a Diabetes Prescription in Disguise
Prescribing outside an approved indication is legal and common, and the FDA regulates what a manufacturer may claim rather than what a licensed clinician may decide. So a person without diabetes can walk out with a Mounjaro script, and that script can be clinically reasonable.
Evidence matched to their body is the thing that person does not get. The label describes people with type 2 diabetes. The trials behind it stopped at 40 weeks for SURPASS-2 and stayed inside diabetic populations. Weight loss on Mounjaro beyond 40 weeks in people without diabetes is not on the label, and we will not pretend otherwise. It is a genuine gap in the record.
Then there is the vial problem. Compounded tirzepatide is not an FDA-approved product, and it is not the drug in any of these trials. A clinic offering tirzepatide should expect one question first: does the box carry an approval and a National Drug Code? That is the check we walk through in how to check a peptide clinic before booking.
43.6 Percent – What the Label Says Goes Wrong First
The price of the 15 mg dose shows up in the same document. In the pooled placebo-controlled trials, gastrointestinal adverse reactions hit 20.4 percent of the placebo group and 37.1, 39.6 and 43.6 percent of the 5, 10 and 15 mg groups. Discontinuation because of those reactions ran 0.4 percent on placebo against 3.0, 5.4 and 6.6 percent on the three doses, and most of it clustered during dose escalation.
One in fifteen people at the top dose stopped because their gut would not cooperate. That is the number to hold next to the weight number, since the people who stop do not appear in the average of the people who continued. This is also why tirzepatide side effects on the label deserve a read before the first injection, and why the dose ladder in Mounjaro dosage is a safety schedule rather than a menu.
Frequently asked questions
Is Mounjaro approved for weight loss?
No. The Mounjaro label lists two indications: glycemic control in adults and in pediatric patients 10 years and older with type 2 diabetes, and reduction of cardiovascular death, heart attack or stroke risk in adults with type 2 diabetes at high cardiovascular risk. Weight management belongs to Zepbound, the separate approval for the same molecule.
How much weight do people lose on Mounjaro?
On the label’s own trials, SURPASS-2 recorded a mean loss of 11.2 kg at 15 mg after 40 weeks, against 5.7 kg on semaglutide 1 mg, in adults with type 2 diabetes whose mean starting weight was 93.8 kg. SURPASS-1 recorded 7.8 kg at 15 mg against 1.0 kg on placebo at week 40.
Is Mounjaro the same as Zepbound?
Both contain tirzepatide, both cap at 15 mg once weekly, and the FDA states in its Zepbound approval notice that the two should not be used in combination. The approvals, the trials and the approved uses differ, which is why the quoted weight results differ.
How much weight do people with type 2 diabetes lose on Zepbound?
The Zepbound label’s Study 2, in adults with obesity or overweight plus type 2 diabetes, recorded 14.7 percent mean loss at 15 mg and 12.8 percent at 10 mg after 72 weeks, against 3.2 percent on placebo, from a mean starting weight of 99.6 kg.
Can a doctor prescribe Mounjaro for weight loss if I do not have diabetes?
A licensed prescriber can prescribe it outside the approved indication, which is what off-label means. The evidence behind that prescription still comes from people with type 2 diabetes, so the expected result for someone without diabetes is an extrapolation rather than a measurement on the label.
Does the 20.9 percent result apply to me?
That figure comes from the Zepbound label’s Study 1, which enrolled adults with obesity or overweight and excluded type 2 diabetes, over 72 weeks, from a mean starting weight of 105.6 kg. It is one group mean. Half of that group did worse than it, and 9.4 percent of the 15 mg arm had no week 72 weight recorded.
What doses does the Mounjaro label list?
The label starts at 2.5 mg once weekly and raises the dose in 2.5 mg steps after at least 4 weeks at the current level, to a maximum of 15 mg weekly. Doses vary by patient, and the escalation belongs to the prescriber, not to a calculator.
Sources: Mounjaro prescribing information, version 40, published 2 September 2026; Zepbound prescribing information, sections 1 and 14.1; FDA, FDA Approves New Medication for Chronic Weight Management, 8 November 2023; Frías JP et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes, NEJM 2021;385:503-515, 5 August 2021; ClinicalTrials.gov record NCT03987919, SURPASS-2.
We are a directory, not a clinic, and this piece is general information rather than medical advice. It cannot replace a conversation with a licensed prescriber who knows your history. Mounjaro and Zepbound are brand-name tirzepatide products approved by the FDA for different uses, and compounded tirzepatide is not FDA-approved. Expectations, doses and eligibility vary by patient, and the prescriber sets them.